Biogenity

Interns are not just extra hands - they are a window into the next generation of talent.

Last week, we said goodbye to Mathilde, who spent the first half of 2026 with us at Biogenity. Her work centred on our R&D efforts within multi-omics integration - exploring and evaluating methods for data analysis and presentation, and mapping the bioinformatics landscape for approaches relevant to our work. A domain that requires both technical depth and the ability to navigate a fast-moving research field.

What stood out was not just the work itself, but how she did it. Independent, solution-oriented, and a genuine contributor to the team.

We are proud of what she delivered, and we look forward to seeing where her studies and career take her next.

𝗢𝗹𝗶𝗻𝗸 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀 𝗶𝗻 𝗿𝗲𝗽𝗿𝗼𝗱𝘂𝗰𝗶𝗯𝗹𝗲 𝗹𝗮𝗿𝗴𝗲-𝗰𝗼𝗵𝗼𝗿𝘁 𝘀𝘁𝘂𝗱𝗶𝗲𝘀
Large cohort studies place high demands on assay robustness and reproducibility. Olink technology is designed to deliver consistent results across runs, operators, and study sizes.

Biogenity supports Olink proteomics projects ranging from pilot studies to large-scale cohorts, ensuring standardized workflows and quality control throughout. This consistency is essential for studies approaching translational or clinical phases.

Planning a large cohort or longitudinal study? Let’s talk about reproducibility, scale, and workflow design.

🔗 https://biogenity.com/olink-proteomics

🧬 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗽𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀 𝗶𝗻 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗯𝗶𝗼𝗹𝗼𝗴𝘆
Clinical proteomics is used when protein-level information is needed to understand disease states, prognosis, or treatment response. By profiling the proteome across patient samples, it supports biomarker discovery and the development of models for patient stratification and personalized medicine.

At Biogenity, clinical proteomics is applied in studies ranging from exploratory biomarker discovery to cohort-based analyses. Combined with bioinformatics, protein profiling enables the identification of disease-associated patterns and protein signatures relevant for clinical research.

This approach is particularly valuable when the goal is to link molecular data with clinical phenotypes and outcomes.

💬 Working with clinical samples and protein biomarkers? Let’s discuss whether clinical proteomics fits your study design.

🔗 https://biogenity.com/clinical-proteomics

🗺️ 𝗢𝗹𝗶𝗻𝗸 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀 𝗶𝗻 𝗵𝘆𝗽𝗼𝘁𝗵𝗲𝘀𝗶𝘀-𝗱𝗿𝗶𝘃𝗲𝗻 𝗮𝗻𝗱 𝗲𝘅𝗽𝗹𝗼𝗿𝗮𝘁𝗼𝗿𝘆 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵
Olink offers a broad portfolio of panels targeting inflammation, oncology, neurology, cardiovascular biology, metabolism, and cell regulation. This flexibility supports both hypothesis-driven studies and broader exploratory research designs.

At Biogenity, panel selection is guided by the underlying biological question, disease context, and study objectives. Aligning panel choice with scientific intent is critical for generating interpretable and impactful results.

Not sure which Olink panel fits your research question? Let’s discuss panel strategy and study alignment.

🔗 https://biogenity.com/olink-proteomics